Optic nerve regeneration

Article

Scientists from the Children's Hospital Boston, USA have revealed their achievement of the greatest regeneration to date in the mammalian optic nerve.

Scientists from the Children's Hospital Boston, USA have revealed their achievement of the greatest regeneration to date in the mammalian optic nerve, which could lead them to potentially be able to restore function after vision loss caused by optic nerve damage.

The scientists have discovered that two molecular pathways, that each promotes some optic nerve regeneration on their own, can work synergistically. Through the simultaneous activation of these pathways in a mouse model there was a 10-fold increase in the regeneration in comparison with results obtained of either pathway alone.

Dr Larry Benowitz, a member of the Neurobiology and Neurosurgery Departments at Children's and a professor of Surgery and Ophthalmology at Harvard Medical School, commented: "This is a really massive change. It brings us closer to potentially restoring function after vision loss caused by optic nerve damage."

For more detailed information visit the website www.childrenshospital.org

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.